Eli Lilly and Company (LLY)/, Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Starting mid-November, Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay, at Walmart pharmacies nationwide.
Notably, the collaboration with Walmart expands convenient access to Zepbound, especially for those who prefer the ease of pickup at their local Walmart pharmacy.
In the pre-market hours, LLY is trading at $826.50, up 0.74 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.